Multiple Sclerosis (MS)

Multiple Sclerosis (MS) research at Department of Neurology at Oslo University Hospital (OUH) aims to identify characteristics and susceptibility factors of MS, to contribute to a better understanding of the disease and development of better treatments. The MS research unit is a member of the Neuroscience Research Unit (NRU). Read about the MS research group in Norwegian on our University of Oslo website and check out our facebook page: MS-forskningsgruppen ved Oslo Universitetssykehus - UiO

Our MS research is organized in four research groups:

Clinical trials:

  • NOR-MS: Comparing treatment with cladribine and rituximab
  • NEVROVAX: Study of responses to vaccination against influenza and COVID-19
  • LEM-PASS: Safety follow-up after treatment with alemtuzumab (Sponsor Sanofi)
  • CLAD-CROSS: A prospective study of safety and efficacy when switching to cladribine (Sponsor Merck)
  • COMB157G23101: A prospective study of efficacy and safety when switching from dimethylfumarate or fingolimod to ofatumumab (Sponsor Novartis)
  • GEMINI: Double blind, randomized study comparing BTKi-inhibitor with teriflunomide in RRMS (Sponsor Sanofi)
  • HERCULES: Double blind, randomized study comparing BTKi-inhibitor with placebo in SPMS (Sponsor Sanofi)
Scroll to top